人工智能在肺癌个性化预后评估中的实施:叙述性审查
Filippo Lococo1,2, Galal Ghaly3, Marco Chiappetta1,2
1Faculty of Medicine and Surgery, Catholic University of Sacred Heart, 00168 Rome, Italy.
Cancers
|May 25, 2024
概括
人工智能 (AI) 增强非小细胞肺癌 (NSCLC) 管理,改善病期,预后和治疗预测. 人工智能集成提供了个性化的护理,但需要解决数据质量和可解释性挑战,以获得更好的患者结果.
科学领域:
- 在瘤学瘤学.
- 医疗成像医学成像
- 人工智能的人工智能
背景情况:
- 非小细胞肺癌 (NSCLC) 的管理涉及复杂的分期,预后评估和治疗决策.
- 目前的方法可能缺乏完全个性化的患者护理的精度.
- 人工智能 (AI) 提供了增强NSCLC管理各方面的机会.
研究的目的:
- 为NSCLC提供AI当前应用的全面概述.
- 分析人工智能算法如何预测分期,预后,治疗反应和复发.
- 突出AI在NSCLC个性化预后评估方面的潜力.
主要方法:
- 在NSCLC中对AI进行初步研究的叙述性综述.
- 分析使用机器学习 (ML) 和深度学习 (DL) 技术的AI算法.
- 整合临床,成像和分子数据用于AI模型开发.
主要成果:
- 人工智能可以使用成像数据和ML准确地分类NSCLC阶段.
- 人工智能模型显示出预测生存率和疾病进展的潜力.
- 人工智能有助于预测手术后的治疗反应和复发模式.
结论:
- 人工智能显著提高了NSCLC的管理,从分期到个性化预后.
- 解决数据质量,可解释性和概括性的挑战至关重要.
- 合作和持续的研究对于最大限度地提高AI在NSCLC护理中的好处至关重要.
相关概念视频
Cancer Survival Analysis
343
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
343
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


